Alendronate for Osteoporosis: A comprehensive overview, clinical updates and the newest innovative formulation
About this course
Prof Dennis Black provides an overview of the anti-fracture efficacy and safety data of alendronate for the treatment of osteoporosis, shared updates on the latest clinical updates that was to be presented at the American Society for Bone and Mineral Research (ASBMR) 2018, and shared the latest innovative buffered formulation of alendronate for the treatment of osteoporosis.
In his lecture, Prof Dennis Black reinforces the anti-fracture efficacy data from the Fracture Intervention Trial (FIT), presents the latest data including his latest large scale epidemiologic study "Atypical femur fractures – Review of epidemiology, relationship to bisphosphonates, prevention and clinical management", provides assurance on the overwhelmingly favourable benefit-risk of bisphosphonate treatment over the very rare occurrences of atypical femoral fractures and osteonecrosis of the jaw, and shares key insights in optimizing long term alendronate treatment for osteoporosis.
Lastly, Prof Dennis Black highlighted the efficacy and safety data of the innovative buffered formulation of alendronate and provides the therapeutic scenarios and key patient profiles where buffered alendronate would be a good and valuable option for healthcare professionals in the management of osteoporotic patients.
1 CME Point Available (Category 3A)
- Complete the videos and quiz to qualify for 1 CME Point (Category 3A).
- A certificate will be provided upon successful completion. Please use the information on the certificate to claim your points via SMC website.
- Doctors who have attended the face-to-face meeting will not be eligible for additional CME points for completing this module.
Professor Dennis M. Black, PhD is a Professor of Epidemiology and Biostatistics at University of California, San Francisco (UCSF). He is Head for the Division of Chronic Diseases at UCSF. His research focus is on osteoporosis and he has headed many large observational studies and randomized trials. He was PI and first author for the Fracture Intervention Trial, the main trial supporting the efficacy of Alendronate to reduce fracture risk, used by approximately 80% of osteoporosis patients on treatment worldwide with main results published in the Lancet. He was also the PI and first author on the HORIZON-PFT, the pivotal trial supporting Zoledronic Acid which was published in New England Journal of Medicine. He has also been the lead author on many other influential papers in the field including a total of 10 papers published in NEJM, JAMA and Lancet.
Prof Dennis Black is the recipient of many prestigious awards, including the American Society for Bone and Mineral Research (ASBMR) Frederic C. Bartter Award 2017, which recognizes outstanding clinical investigation in disorders of bone and mineral metabolism. He is current leading the Foundation for NIH (FNIH) Bone Quality Project with a goal of establishing a surrogate measure for fractures which will greatly facilitate future clinical trials and development of new osteoporosis medications. In addition, he has a strong interest in atypical femur fracture and is leading two large epidemiologic projects on atypical femur fracture.
Organized by Osteoporosis Society (Singapore)
An educational talk supported by Zuellig Pharma